VYZULTA dosing, administration, and storage

Convenient once-daily dosing1

  • One drop in the conjunctival sac of the affected eye(s) once daily in the evening
  • Do not administer more than once daily

Administration: patient information1

Patients should be instructed to:

  • Avoid allowing container tip to contact any surface, in order to avoid contamination with ocular infection-causing bacteria
  • Administer other topical ophthalmic IOP drugs at least 5 minutes apart
  • Remove contact lenses prior to administration. Lenses may be reinserted 15 minutes after administration

Storage before and after opening1

  • Unopened bottles should be refrigerated at 2° to 8°C (36° to 46°F)
  • Once a bottle is opened, it can be stored at 2° to 25°C (36° to 77°F) for 8 weeks
INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
1. VYZULTA Prescribing Information. Bausch & Lomb Incorporated. 2018.

SEE MORE

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation